| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.6 | 3.5 |
| Gross profit | 1.8 | 1.9 |
| Profit before tax | -7.3 | -7.9 |
| Net income | -7.3 | -7.9 |
| EPS (diluted, $ a share) | $-0.15 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +0.8% |
|---|---|
| Gross margin | 49.4% |
| Operating margin | -207.0% |
10-Q filed with the SEC, NASDAQ: CV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CapsoVision, Inc: key numbers
- Share price
- $6.47Close, Nov 16
- Market cap
- $347M
- Shares outstanding
- 53.61MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CapsoVision, Inc
All →CapsoVision Financial Results
CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.
- Term
- Q3 2026
“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”
Johnny Wang, President and Chief Executive Officer
“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”
Johnny Wang, President and Chief Executive Officer
CapsoVision Regulatory Approval
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.
CapsoVision Insider Eliyahou Et Al Harari Buys $10M of Stock
Eliyahou Et Al Harari bought 1,757,469 shares of CapsoVision, Inc at $5.69 a share, worth $10M in total on Sep 18, 2026. Shares held after the trade: 878,734.
- Value
- $10M
- Shares
- 1,757,469
- Average price
- $5.69
- Trade date
- Sep 18, 2026
CapsoVision Insider Ching Hang Shen Buys $5M of Stock
Ching Hang Shen bought 878,734 shares of CapsoVision, Inc at $5.69 a share, worth $5M in total on Sep 15, 2026. Shares held after the trade: 2,926,655 (+42.9%).
- Value
- $5M
- Shares
- 878,734
- Price
- $5.69
- Holding change
- +42.9%
- Trade date
- Sep 15, 2026
CapsoVision Capital Raise of $18M
CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share. The offering raised approximately $18 million in gross proceeds from existing stockholders, including major investors Star One Global Capital Limited and Eliyahou Harari. The company intends to use the proceeds for general corporate purposes, including R&D and sales and marketing.
- Value
- $18M
- Counterparty
- Star One Global Capital Limited and Eliyahou Harari